» Articles » PMID: 32211116

Downregulated MiR-203 Attenuates IL-β, IL-6, and TNF-α Activation in TRAF6-treated Human Renal Mesangial and Tubular Epithelial Cells

Overview
Specialty Pathology
Date 2020 Mar 27
PMID 32211116
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Circulating microRNAs (miRNAs) are attracting major interest as novel non-invasive biomarkers for human autoimmune diseases including lupus nephritis (LN). A previous study showed that altered miR-203 expression may provide highly diagnostic for systemic lupus erythematosus. However, whether miR-203 is a diagnostic biomarker for LN is still unknown. In the present research, serum samples from 35 cases of active LN patients, 58 cases of inactive LN patients, and 74 cases of healthy volunteers were collected to analyze the expression profiles of miR-203 by qRT-PCR. The serum concentration of complement component 3 (C3) and complement component 4 (C4) was detected using nephelometry method. The expression of inflammatory cytokines, including interleukin 1 beta (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α), were analyzed using enzyme-linked immunosorbent assay (ELISA). The effect of miR-203 overexpression on the TNF receptor associated factor 6 (TRAF6)-induced inflammation of human renal mesangial cells (HRMCs) and human renal tubular epithelial cell line (HK-2) were evaluated. Results showed that miR-203 in serum of active LN patients was significantly down-regulated when compared with serum from inactive LN patients and healthy volunteers. Receiver operating curve (ROC) showed that decreased circulating miR-203 was a significant diagnostic biomarker for active LN patients, with an area under curve (AUC) of 0.974; sensitivity was 85.79%, and specificity was 89.40%. Significant downregulation of C3 and C4, and obvious upregulation of IL-β, IL-6, and TNF-α, was observed in serum of active LN patients. Furthermore, circulating miR-203 expression was positively correlated with the serum concentrations of C3 and C4, and negatively correlated with the serum expression of IL-1β, IL-6, and TNF-α in active LN patients. In addition, transfection of HRMCs and HK-2 cells with miR-203 mimics could suppress TRAF6-induced IL-β, IL-6, or TNF-α expression compared to cells treated with the mimics control group. In summary, decreased circulating miR-203 might be a candidate diagnostic biomarker for human active LN, and it attenuated IL-β, IL-6, and TNF-α activation in TRAF6-treated HRMCs and HK-2 cells.

Citing Articles

MicroRNA-203 Expression as Potential Biomarker for Lupus Nephritis.

Setyawan Y, Susianti H, Sulistyarti H, Khrisna M, Mayashinta D, Fitri L Int J Nephrol Renovasc Dis. 2025; 18:53-58.

PMID: 39990192 PMC: 11844303. DOI: 10.2147/IJNRD.S485409.


Role of microRNAs in Diabetes-Associated Periodontitis: A Scoping Review.

Agnihotri R, Gaur S, Bhat S J Int Soc Prev Community Dent. 2024; 14(3):180-191.

PMID: 39055291 PMC: 11268527. DOI: 10.4103/jispcd.jispcd_3_24.


Timing Expression of miR203a-3p during OA Disease: Preliminary In Vitro Evidence.

Costa V, De Fine M, Raimondi L, Bellavia D, Cordaro A, Carina V Int J Mol Sci. 2023; 24(5).

PMID: 36901745 PMC: 10002134. DOI: 10.3390/ijms24054316.


Mesangial cell: A hub in lupus nephritis.

Liu M, Zhang L, Wang Y, Hu W, Wang C, Wen Z Front Immunol. 2023; 13:1063497.

PMID: 36591251 PMC: 9795068. DOI: 10.3389/fimmu.2022.1063497.


Progress in the application of body fluid and tissue level mRNAs-non-coding RNAs for the early diagnosis and prognostic evaluation of systemic lupus erythematosus.

Liang J, Xie F, Feng J, Huang C, Shen J, Han Z Front Immunol. 2022; 13:1020891.

PMID: 36325322 PMC: 9618628. DOI: 10.3389/fimmu.2022.1020891.


References
1.
Li H, Ning Y, Li S, Shao P, Chen S, Ye Q . Expression and clinical significance of miR-181a and miR-203 in systemic lupus erythematosus patients. Eur Rev Med Pharmacol Sci. 2017; 21(21):4790-4796. View

2.
Yu F, Haas M, Glassock R, Zhao M . Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017; 13(8):483-495. DOI: 10.1038/nrneph.2017.85. View

3.
Ye H, Hao H, Wang J, Chen R, Huang Z . miR-203 as a novel biomarker for the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis. Onco Targets Ther. 2017; 10:3685-3696. PMC: 5533489. DOI: 10.2147/OTT.S134252. View

4.
Mubarak M, Nasri H . ISN/RPS 2003 classification of lupus nephritis: time to take a look on the achievements and limitations of the schema. J Nephropathol. 2014; 3(3):87-90. PMC: 4119328. DOI: 10.12860/jnp.2014.17. View

5.
Lin X, Chen H, Zhan X . MiR-203 regulates JAK-STAT pathway in affecting pancreatic cancer cells proliferation and apoptosis by targeting SOCS3. Eur Rev Med Pharmacol Sci. 2019; 23(16):6906-6913. DOI: 10.26355/eurrev_201908_18730. View